ARFGAP3

Across TCGA pan-cancer cohorts, ARFGAP3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARFGAP3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ARFGAP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARFGAP3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SKCM, KICH, and COAD are the cancer types where ARFGAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.382	0.783	.009	6	view →
KICH	DFS	Median	All	0.121	0.867	.023	5	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
BLCA	DFS	Median	III,IV	1.000	0.270	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARFGAP3–SKCM (OS)

Open the SKCM breakdown →